Gene therapy adds or replaces genetic material in your cells, cell therapy puts living cells into your body, and gene editing precisely rewrites the DNA already there. They are the three pillars of what the industry calls advanced therapies, and they are frequently confused because they overlap: some of the most famous treatments are two or three of these at once. Here is how to keep them straight.
Gene therapy: fixing the instructions
Your cells run on genetic instructions written in DNA. When a disease is caused by a faulty or missing gene, gene therapy aims to fix the problem at the source by delivering functional genetic material into the patient’s cells, giving them the correct instructions. The delivery is usually done with a vector, most often a harmless engineered virus (such as an adeno-associated virus or a lentivirus) that ferries the therapeutic gene into cells. Gene therapy can be done in vivo, where the vector is infused directly into the patient and finds its target inside the body, or ex vivo, where cells are removed, modified in the lab, and returned. The promise is enormous: for some inherited diseases, a single gene therapy can offer a lasting, potentially one-time treatment where before there was only lifelong management.
Cell therapy: delivering living cells
Cell therapy treats disease by putting living cells into a patient. Those cells might be stem cells that can regenerate damaged tissue, or immune cells trained to fight disease. The cells can come from the patient themselves (autologous) or from a donor (allogeneic). The most celebrated example is CAR-T therapy, used against certain blood cancers: a patient’s own immune T-cells are collected, and then reprogrammed to recognize and attack cancer, and infused back in. Cell therapy is fundamentally about the therapeutic power of living cells, whether to rebuild, replace, or defend.
Gene editing: rewriting the code precisely
Where classic gene therapy adds a new gene, gene editing changes the existing DNA in place, with precision. Tools like CRISPR act as molecular scissors that can cut DNA at a targeted location so a sequence can be disabled, corrected, or altered. Newer techniques, such as base editing and prime editing, aim to rewrite DNA even more precisely, changing individual letters of the genetic code without cutting both strands. Gene editing is less a standalone product category than a powerful technique, and it is increasingly used inside gene and cell therapies to make them more precise. It is one of the most consequential scientific tools of our era.
Where the three overlap (and why people get confused)
Here is why the terms tangle: many real therapies are combinations of all three. CAR-T is the clearest case. It is a cell therapy (living T-cells are infused), but those cells are genetically modified to carry a new receptor, which makes it a gene therapy too. And the newest versions use gene editing to engineer the cells more precisely. Similarly, a landmark approved treatment for sickle cell disease works by editing the genes of a patient’s own blood stem cells outside the body and returning them, blending gene editing, gene therapy, and cell therapy into one product. So the categories are not walls; they are overlapping tools that developers mix and match. When someone asks whether a therapy is gene or cell therapy, the honest answer is often “both.”
The three at a glance
| Approach | What it does | Classic example |
|---|---|---|
| Gene therapy | Adds or replaces genetic material in cells | AAV gene therapy for an inherited disease |
| Cell therapy | Delivers living cells into the patient | Stem cell therapy; CAR-T (also gene-modified) |
| Gene editing | Precisely rewrites existing DNA | CRISPR-based therapy for sickle cell disease |
Why these fields are both thrilling and hard
Advanced therapies represent some of the most exciting science in medicine, offering potentially curative, sometimes one-time treatments for diseases that were once untreatable. But they are extraordinarily difficult to manufacture, deliver, and pay for. Producing a living cell product or a viral vector is far more complex than making a pill, the manufacturing is often inseparable from the product itself, and the treatments can be staggeringly expensive. The science increasingly works; the harder challenges now are scaling production, reaching patients through specialized treatment centers, and building payment models that make these one-time cures viable. That tension, breathtaking biology meeting stubborn operational and economic reality, defines the field today.
Why these therapies are so hard to make and so expensive
The science of advanced therapies is dazzling, but the economics and logistics are where the field strains, and understanding why explains a great deal about the headlines. Manufacturing is the core challenge. Making a living cell product or a viral vector is nothing like producing a pill: the process is complex, sensitive, and in many cases inseparable from the product itself, so the manufacturing method effectively is the drug. For autologous cell therapies, where a patient’s own cells are collected, engineered, and returned, each dose is in a sense a bespoke product with a tight, unforgiving timeline. This is why manufacturing capacity, and especially the shortage of viral-vector production, is one of the biggest bottlenecks in the entire field.
Delivery is equally demanding. Many advanced therapies must be administered at specialized treatment centers with the expertise to handle complex procedures, which limits how many patients can realistically be reached. And then there is price: these can be among the most expensive treatments ever developed, sometimes carrying seven-figure price tags, which collides with reimbursement systems built for chronic, repeat medication rather than one-time cures. Payers and companies are experimenting with new payment models, including arrangements that tie payment to whether the therapy actually works over time, but the economics remain unsettled. The through-line is that the biology increasingly works; the manufacturing, delivery, and payment systems around it are what will determine whether these breakthroughs reach patients at scale, and that is exactly where the field’s hardest problems now sit.
Where the field is heading
The frontier of advanced therapies is moving in a few clear directions worth watching. Gene editing is advancing from cutting DNA toward more precise rewriting, with base and prime editing aiming to change the genetic code more cleanly and safely. There is a strong push to deliver editing and gene therapy directly inside the body rather than requiring cells to be removed and re-infused, which would dramatically simplify treatment if it can be made to work reliably. And in cell therapy, much effort is going into off-the-shelf, donor-derived products that could be manufactured at scale and stored ready to use, rather than made individually for each patient. Alongside the science, the field is working hard on the unglamorous problems that determine real-world impact: cheaper and more scalable manufacturing, simpler delivery, and payment models suited to one-time cures. The common thread is a maturation from proving the biology works toward making it practical, affordable, and widely available, which is exactly the transition that will decide how many patients these remarkable technologies ultimately reach.
The takeaway
Hold the three ideas in your head this way: gene therapy changes the genetic instructions, cell therapy delivers living cells, and gene editing precisely rewrites the DNA that is already there. The reason they blur is that the most powerful treatments combine them, a reprogrammed immune cell, a gene-edited stem cell returned to a patient, so the honest answer to “which one is it” is frequently “more than one.” What unites them is the ambition to treat disease at its most fundamental level, and what challenges them is the difficulty of manufacturing, delivering, and paying for such complex medicines. Understanding the distinctions, and the overlaps, is the foundation for following one of the most important stories in modern medicine.
To follow the breakthroughs, approvals, and manufacturing developments across advanced therapies, the BioMed Nexus brief covers the space daily, and the gene and cell therapy directory maps the companies building these treatments, from platform pioneers to the specialists solving the manufacturing bottleneck.
Frequently asked questions
What is the difference between gene therapy and cell therapy?
Gene therapy adds or replaces genetic material inside a patient's cells to correct a faulty or missing gene, usually delivered by an engineered virus. Cell therapy treats disease by putting living cells, such as stem cells or reprogrammed immune cells, into the patient. Many therapies, like CAR-T, are both at once.
Is gene editing the same as gene therapy?
Not exactly. Gene therapy typically adds a new gene to a cell, while gene editing precisely rewrites the existing DNA in place using tools like CRISPR, base editing or prime editing. Gene editing is best understood as a technique that is increasingly used inside gene and cell therapies to make them more precise.
Is CAR-T a gene therapy or a cell therapy?
CAR-T is both. It is a cell therapy because living immune T-cells are infused into the patient, and a gene therapy because those cells are genetically modified to carry a new receptor that targets cancer. Newer versions also use gene editing to engineer the cells, making it an overlap of all three approaches.
